Publications by authors named "C A Carina Steendam"
The aim was to determine ileal endogenous nitrogen losses (ENL) and true ileal N-digestibility (TD-N) under non-steady-state conditions of the N-isotope dilution technique (N-IDT), using diets generating low and high ENL and compare results to those obtained under steady-state conditions. Twelve growing pigs (mean LW 22.4 kg) fitted with a post-valve T-caecum cannula were fed an enzyme-hydrolysed casein (EHC)-based diet or an EHC diet + 4% quebracho tannins (QT) and were labelled via continuous N-leucine .
View Article and Find Full Text PDFIntroduction: Brain metastases (BM) are common in patients with advanced -mutated (m+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic failure due to low plasma trough levels (C) and consequently limited intracranial osimertinib exposure.
View Article and Find Full Text PDFArticle Synopsis
- This study focuses on understanding how non-small cell lung cancer (NSCLC) develops resistance to the drug erlotinib, with the goal of optimizing cancer treatments.
- It utilizes data from multiple patient studies, examining drug concentrations, tumor sizes, and circulating tumor DNA (ctDNA) to characterize tumor dynamics and how they relate to treatment response.
- Findings suggest that high levels of baseline ctDNA mutations correlate with faster tumor growth and that using ctDNA measurements could help predict the effectiveness of cancer treatments and improve treatment strategies.
Osimertinib is prescribed to patients with metastatic non-small cell lung cancer (NSCLC) and a sensitizing EGFR mutation. Limited data exists on the impact of patient characteristics or osimertinib exposure on effectiveness outcomes. This was a Dutch, multicenter cohort study.
View Article and Find Full Text PDFArticle Synopsis
- This study focuses on the effectiveness of chemotherapy treatments for patients with EGFR-mutated non-small cell lung cancer (NSCLC) after they have stopped responding to EGFR-tyrosine kinase inhibitors (TKIs).
- Researchers analyzed data from two medical centers in the Netherlands, looking at 171 instances of chemotherapy to measure best responses, progression-free survival (PFS), and overall survival (OS).
- Results indicated that patients had significant benefits from various chemotherapy regimens, particularly platinum/pemetrexed and carboplatin/paclitaxel/bevacizumab/atezolizumab in first-line treatment, while showing no significant differences in survival rates among different treatment combinations.